Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes

医学 前列腺癌 随机对照试验 内科学 肿瘤科 放射治疗 临床试验 癌症 危险系数 置信区间
作者
Safae Terrisse,Eleni Karamouza,Chris Parker,A. Oliver Sartor,Nicholas D. James,Sarah Pirrie,Laurence Collette,Bertrand Tombal,Jad Chahoud,Sigbjørn Smeland,Bjørn Erikstein,Jean‐Pierre Pignon,Karim Fizazi,Gwénaël Le Teuff
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (2): 206-206 被引量:21
标识
DOI:10.1001/jamaoncol.2019.4097
摘要

Importance

Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an overall survival (OS) benefit from an α-emitting RI, radium 223 (223Ra), vs standard of care. Yet no head-to-head comparison has been done between α-emitting and β-emitting RIs.

Objective

To assess OS in men with bone metastases from CRPC treated with bone-targeted RIs and to compare the effects of α-emitting RIs with β-emitting RIs.

Data Sources

PubMed, Cochrane Library, ClinicalTrials.gov, and meeting proceedings between January 1993 and June 2013 were reviewed. Key terms includedrandomized trials,radioisotopes,radiopharmaceuticals, andprostate cancer. Data were collected, checked, and analyzed from February 2017 to October 2018.

Study Selection

Selected trials included patients with prostate cancer, recruited more than 50 patients from January 1993 to June 2013, compared RI use with no RI use (placebo, external radiotherapy, or chemotherapy), and were randomized. Patients were diagnosed with histologically proven prostate cancer and disease progression after both surgical or chemical castration and have evidence of bone metastasis. Nine randomized clinical trials were identified as eligible, but 3 were excluded for insufficient data.

Data Extraction and Synthesis

Individual patient data were requested for each eligible trial, and all data were checked with a standard procedure. The log-rank test stratified by trial was used to estimate hazard ratios (HRs), and a similar fixed-effects (FE) model was used to estimate odds ratios (ORs). The between-trial heterogeneity of treatment effects was evaluated by Cochran test andI2and was accounted by a random-effects (RE) model.

Main Outcomes and Measures

Overall survival; secondary outcomes were symptomatic skeletal event (SSE)–free survival and adverse events.

Results

Based on 6 randomized clinical trials including 2081 patients, RI use was significantly associated with OS compared with no RI use (HR, 0.86; 95% CI, 0.77-0.95;P = .004) with high heterogeneity (χ25 = 24.46;P < .001;I2 = 80%), but this association disappeared when using an RE model (HR, 0.80; 95% CI, 0.61-1.06;P = .12; τ2 = 0.08). The heterogeneity is explained both by the type of RI and by the inclusion of 2 outlier trials that included 275 patients; the OS benefit was significantly higher with the α-emitting RI223Ra (HR, 0.70; 95% CI, 0.58-0.83) but not significant with the β-emitting RI strontium-89 (HR, 0.96; 95% CI, 0.84-1.10) (Pfor interaction = .004). Excluding the outlier trials led to an overall HR of 0.82 (95% CI, 0.73-0.92;P < .001) (between-trial heterogeneity: χ23 = 6.51;P = .09;I2 = 54%) using an FE model and an HR of 0.80 (95% CI, 0.65-0.99;P = .04; τ2 = 0.02) using an RE model. The HR for SSE-free survival was 0.81 (95% CI, 0.69-0.93;P = .004) (between-trial heterogeneity: χ23 = 6.71;P = .08;I2 = 55%) when using an FE model and was 0.76 (95% CI, 0.58-1.01;P = .06; τ2 = 0.04) when using an RE model. There were more hematological toxic effects with RI use compared with no RI use (OR, 1.48; 95% CI, 1.17-1.88;P = .001).

Conclusions and Relevance

In metastatic CRPC, a significant improvement of OS and SSE-free survival was obtained with bone-targeted α-emitting but not β-emitting RIs. Caution is necessary for generalizability of these results, given the between-trial heterogeneity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
didi完成签到,获得积分10
1秒前
zzy加油发布了新的文献求助10
1秒前
李保龙完成签到 ,获得积分10
1秒前
Crazykk完成签到,获得积分10
2秒前
guoguo发布了新的文献求助30
2秒前
2秒前
顾矜应助白茶采纳,获得10
2秒前
张美玲发布了新的文献求助10
3秒前
Hello应助shiyaouao采纳,获得10
3秒前
鱼香肉丝完成签到,获得积分10
3秒前
fy207发布了新的文献求助10
4秒前
wsy完成签到,获得积分10
4秒前
领导范儿应助lele7458采纳,获得10
5秒前
研友_LX0JxL发布了新的文献求助30
6秒前
小学渣完成签到,获得积分10
7秒前
蓝天阳光完成签到,获得积分10
8秒前
子虞完成签到,获得积分10
8秒前
wy.he应助MrPao采纳,获得10
8秒前
9秒前
时光完成签到,获得积分10
9秒前
英姑应助满意芯采纳,获得10
9秒前
飞云发布了新的文献求助10
10秒前
负责的谷槐完成签到,获得积分20
10秒前
zzz关闭了zzz文献求助
10秒前
沐沐完成签到 ,获得积分20
11秒前
summer完成签到,获得积分10
14秒前
14秒前
14秒前
王哥完成签到,获得积分10
14秒前
fy207完成签到,获得积分10
14秒前
14秒前
15秒前
心灵美的幼蓉完成签到,获得积分10
15秒前
彼得大帝完成签到,获得积分10
15秒前
科研小子完成签到 ,获得积分10
15秒前
wind完成签到,获得积分10
15秒前
15秒前
CyrusSo524应助djbj2022采纳,获得10
16秒前
16秒前
天问完成签到,获得积分10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969033
求助须知:如何正确求助?哪些是违规求助? 3513900
关于积分的说明 11170818
捐赠科研通 3249256
什么是DOI,文献DOI怎么找? 1794708
邀请新用户注册赠送积分活动 875326
科研通“疑难数据库(出版商)”最低求助积分说明 804759